GSK has paid $50 million upfront to partner with LTZ Therapeutics on myeloid cell engagers, expanding its cancer pipeline to cover a modality that has attracted Eli Lilly, Novartis, Pfizer and Sanofi.

GSK teams with LTZ Therapeutics to co-develop next-gen myeloid-cell engager immunotherapies in oncology leveraging LTZ’s ...

Just a few weeks after the company announced licensing agreements with Empirico and Syndivia, GSK announced a strategic ...

GlaxoSmithKline ( ($GB:GSK) ) has shared an announcement. GSK plc announced the acquisition of American Depositary Shares (ADSs) by Dr. Hal ...

Drug resistance — known as antimicrobial resistance, or AMR — emerges when pathogens mutate in ways that make treatments ...

GSK funding allocated to six new research programmes which will combine expertise and using cutting edge AI technology to ...

By Kamal Choudhury (Reuters) -Shares of AnaptysBio fell more than 5% on Friday after the U.S. drug developer and GSK's oncology unit, Tesaro, filed lawsuits against each other, with both claiming a ...

Dr. Emmanuel Hanon will be focused on advancing Viome's precision therapeutics platform intended to prevent chronic diseases, cancer, and aging. BELLEVUE, Wash., April 15, 2021 /PRNewswire/ -- Viome, ...

According to GSK, the programme of 'Grand Challenge' research projects will make use of AI and other cutting-edge ...

The FINANCIAL — GSK will inaugurate its newest global vaccines research and development (R&D) center in Rockville, Maryland, further strengthening and expanding its vaccines presence in the USA. Up to ...

GSK’s leadership in respiratory medicine goes beyond science—uniting research, collaboration, and care to transform outcomes ...

SOUTH SAN FRANCISCO, Calif. and LONDON, July 02, 2021 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC) and GlaxoSmithKline plc (LSE/NYSE: GSK), today announced a strategic global collaboration for the ...